Pharmaceuticals, Biotechnology and Life Sciences
MELBOURNE, Australia and INDIANAPOLIS, Sept. 24, 2025 (GLOBE NEWSWIRE) — Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces…
KEY LARGO, Fla., Sept. 23, 2025 (GLOBE NEWSWIRE) — Remedy’s Nutrition®, a trusted natural dietary supplement company since 1972 and…
LOS ANGELES, Sept. 23, 2025 (GLOBE NEWSWIRE) — Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical company developing first-in-class therapies for…
PALO ALTO, Calif., Sept. 23, 2025 (GLOBE NEWSWIRE) — Scilex Holding Company (“Scilex” or the “Company”) (Nasdaq: SCLX), an innovative…
DURHAM, N.C., Sept. 22, 2025 (GLOBE NEWSWIRE) — Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (CRO),…
CARMEL, Ind., Sept. 22, 2025 (GLOBE NEWSWIRE) — MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the…
Cash and cash equivalents totaled €107.5 million as of June 30, 2025, excluding the €26.5 million milestone invoiced in May…
VICTORIA, British Columbia, Sept. 22, 2025 (GLOBE NEWSWIRE) — Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology…
Interim Clinical Study Results for Cohort 1 of the BB-301 Phase 1b/2a Treatment Study Anticipated in Q4 2025 Enrollment of…
This investment, led by Founders Fund with participation from Lux Capital and Field Ventures, brings total investment to date to…